Investor Relations

View pipeline chart

We have applied our expertise in multivalency to discover product candidates and lead compounds in a number of therapeutic areas.


Theravance (NASDAQ: THRX) is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.

Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. The Company's key programs include: RELVAR®/BREO® ELLIPTA® (FF/VI), ANOROTM ELLIPTATM (UMEC/VI) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist) GSK961081, each partnered with GlaxoSmithKline plc (GSK), and our Long-Acting Muscarinic Antagonist program. By leveraging its proprietary insight of multivalency to drug discovery, Theravance is pursuing a best-in-class strategy designed to discover superior medicines in areas of significant unmet medical need.

View all »   RSSRecent Releases

Apr 22, 2014
GSK and Theravance Announce Phase III Study of Fluticasone Furoate/Vilanterol in COPD Commenced to Support Potential Future Filing in Japan

Apr 21, 2014
Theravance Closes Private Placement of $450 Million of 9% Non-Recourse Notes Supporting Strategic Separation Process

View all »Presentations & Events

May 6, 2014 at 2:00 PM PT
Theravance First Quarter 2014 Financial Results Conference Call

Investor Relations
Proxy Materials
Form content here please :)